Hepatic CYP2A6 levels and nicotine metabolism: impact of genetic, physiological, environmental, and epigenetic factors

European Journal of Clinical Pharmacology

Volumn 66, Issue 3, 2010, Pages 239-251

  Al Koudsi, Nael ^a   Hoffmann, Ewa B ^a,b   Assadzadeh, Abbas ^a   Tyndale, Rachel F ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

Age; CYP2A6; Gender; Nicotine; Pharmacogenetics

Indexed keywords

CYTOCHROME P450 2A6; DEXAMETHASONE; DNA; MESSENGER RNA; NICOTINE; PHENOBARBITAL; COUMARIN 7 HYDROXYLASE; COUMARIN 7-HYDROXYLASE; UNSPECIFIC MONOOXYGENASE;

ADOLESCENT; ADULT; AGING; ARTICLE; BINDING AFFINITY; CELL STRAIN HEPG2; CHILD; CONTROLLED STUDY; CPG ISLAND; CRYOPRESERVATION; DNA METHYLATION; DRUG EXPOSURE; ENVIRONMENTAL FACTOR; EPIGENETICS; FEMALE; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HEREDITY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL; MAJOR CLINICAL STUDY; MALE; OXIDATION; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; SEX DIFFERENCE; AGE; CHI SQUARE DISTRIBUTION; DRUG EFFECT; ENZYMOLOGY; GENETIC EPIGENESIS; GENETICS; KINETICS; LIVER; LIVER MICROSOME; METABOLISM; MIDDLE AGED; OXIDATION REDUCTION REACTION; PHENOTYPE; PRESCHOOL CHILD; STATISTICAL MODEL;

ADOLESCENT; ADULT; AGE FACTORS; ARYL HYDROCARBON HYDROXYLASES; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; CPG ISLANDS; DEXAMETHASONE; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENOTYPE; HEP G2 CELLS; HEPATOCYTES; HUMANS; KINETICS; LINEAR MODELS; LIVER; MALE; MICROSOMES, LIVER; MIDDLE AGED; NICOTINE; OXIDATION-REDUCTION; PHENOBARBITAL; PHENOTYPE; RNA, MESSENGER; SEX FACTORS; YOUNG ADULT;

EID: 77951916017     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-009-0762-0     Document Type: Article

References (43)

1. Pelkonen O, Rautio A, Raunio H, Pasanen M (2000) CYP2A6: a human coumarin 7-hydroxylase. Toxicology 144(1-3):139-147. doi:S0300483X99002000 [pii]
2. Benowitz NL (2009) Pharmacology of nicotine: addiction, smokinginduced disease, and therapeutics. Annu Rev Pharmacol Toxicol 49:57-71. doi:10.1146/annurev.pharmtox.48.113006.094742
3. Ho MK, Tyndale RF (2007) Overview of the pharmacogenomics of cigarette smoking. Pharmacogenomics J 7(2):81-98. doi:6500436 [pii] 10.1038/sj.tpj.6500436 (Pubitemid 46577845)
4. Benowitz NL, Jacob P 3rd (1994) Metabolism of nicotine to cotinine studied by a dual stable isotope method. Clin Pharmacol Ther 56(5):483-493
5. Messina ES, Tyndale RF, Sellers EM (1997) A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J Pharmacol Exp Ther 282(3):1608-1614
6. Nakajima M, Yamamoto T, Nunoya K, Yokoi T, Nagashima K, Inoue K, Funae Y, Shimada N, Kamataki T, Kuroiwa Y (1996) Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab Dispos 24(11):1212-1217
7. Nakajima M, Fukami T, YamanakaH,Higashi E, SakaiH,Yoshida R, Kwon JT, McLeod HL, Yokoi T (2006) Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Clin Pharmacol Ther 80(3):282-297. doi: S0009-9236(06)00204-209 [pii] 10.1016/j.clpt.2006.05.012 (Pubitemid 44313906)
8. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270(1):414-423
9. Rodriguez-Antona C, Donato MT, Pareja E, Gomez-Lechon MJ, Castell JV (2001) Cytochrome P-450 mRNA expression in human liver and its relationship with enzyme activity. Arch Biochem Biophys 393(2):308-315. doi:10.1006/abbi.2001. 2499 S0003986101924993 [pii]
10. Mwenifumbo JC, Al Koudsi N, Ho MK, Zhou Q, Hoffmann EB, Sellers EM, Tyndale RF (2008)Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent. Hum Mutat 29(5):679-688. doi:10.1002/humu.20698 (Pubitemid 351614592)
11. Haberl M, Anwald B, Klein K, Weil R, Fuss C, Gepdiremen A, Zanger UM, Meyer UA, Wojnowski L (2005) Three haplotypes associated with CYP2A6 phenotypes in Caucasians. Pharmacogenet Genomics 15(9):609-624. doi:01213011-200509000- 200600002 [pii]
12. *9). Pharmacogenetics 13(11):689-695. doi:10.1097/01. fpc.0000054136.14659.be
13. *19) that affect enzymatic activity. Drug Metab Dispos 33(8):1202-1210. doi: dmd.105.004994 [pii] 10.1124/dmd.105.004994 (Pubitemid 41043764)
14. Benowitz NL, Lessov-Schlaggar CN, Swan GE, Jacob P 3rd (2006) Female sex and oral contraceptive use accelerate nicotine metabolism. Clin Pharmacol Ther 79(5):480-488. doi:S0009-9236(06)00033-36 [pii] 10.1016/j.clpt.2006.01.008
15. Molander L, Hansson A, Lunell E (2001) Pharmacokinetics of nicotine in healthy elderly people. Clin Pharmacol Ther 69(1):57-65. doi:S0009-9236(01) 99195-7 [pii] 10.1067/mcp. 2001.113181
16. Ho M, Mwenifumbo J, Al Koudsi N, Okuyemi K, Ahluwalia J, Benowitz N, Tyndale R (2009) Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers. Clin Pharmacol Ther. doi: clpt200919 [pii] 10.1038/clpt.2009.19
17. Hukkanen J, Jacob P 3rd, Benowitz NL (2006) Effect of grapefruit juice on cytochrome P450 2A6 and nicotine renal clearance. Clin Pharmacol Ther 80(5):522-530. doi:S0009-9236 (06)00329-338 [pii] 10.1016/j.clpt.2006.08.006 (Pubitemid 44767880)
18. MauriceM, Emiliani S, Dalet-Beluche I, Derancourt J, Lange R (1991) Isolation and characterization of a cytochrome P450 of the IIA subfamily from human liver microsomes. Eur J Biochem 200(2):511-517
19. Gomez A, Ingelman-Sundberg M (2009) Pharmacoepigenetics: its role in interindividual differences in drug response. Clin Pharmacol Ther 85(4):426-430. doi:clpt20092 [pii] 10.1038/clpt.2009.2
20. Schumacher A, Petronis A (2006) Epigenetics of complex diseases: from general theory to laboratory experiments. Curr Top Microbiol Immunol 310:81-115
21. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C (2007) Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116(3):496-526. doi:S0163-7258(07) 00201-X [pii] 10.1016/j.pharmthera.2007.09.004 (Pubitemid 350116943)
22. Ling G, Wei Y, Ding X (2007) Transcriptional regulation of human CYP2A13 expression in the respiratory tract by CCAAT/enhancer binding protein and epigenetic modulation. Mol Pharmacol 71 (3):807-816. doi:mol.106.031104 [pii] 10.1124/mol.106.031104 (Pubitemid 46294092)
23. Campbell ME, Grant DM, Inaba T, Kalow W (1987) Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P-450 in human liver microsomes. Drug Metab Dispos 15(2):237-249
24. Meier PJ, Mueller HK, Dick B, Meyer UA (1983) Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation. Gastroenterology 85(3):682-692. doi:S0016508583002176 [pii]
25. Pearce RE, McIntyre CJ, Madan A, Sanzgiri U, Draper AJ, Bullock PL, Cook DC, Burton LA, Latham J, Nevins C, Parkinson A (1996) Effects of freezing, thawing, and storing human liver microsomes on cytochrome P450 activity. Arch Biochem Biophys 331(2):145-169. doi:S0003-9861(96)90294-90295 [pii] 10.1006/abbi.1996.0294 (Pubitemid 26256063)
26. Yamazaki H, Inoue K, Turvy CG, Guengerich FP, Shimada T (1997) Effects of freezing, thawing, and storage of human liver samples on the microsomal contents and activities of cytochrome P450 enzymes. Drug Metab Dispos 25(2):168-174
27. Schoedel KA, Hoffmann EB, Rao Y, Sellers EM, Tyndale RF (2004) Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics 14(9):615-626. doi:00008571-200409000-200500006 [pii]
28. *35)) resulting in an amino-acid substitution (Asn438Tyr) is associated with lower CYP2A6 activity in vivo. Pharmacogenomics J. doi:tpj200911 [pii] 10.1038/tpj.2009.11
29. *21 allele using in vivo nicotine kinetics. Eur J Clin Pharmacol 62(6):481-484. doi:10.1007/s00228- 006-0113-3 (Pubitemid 43873720)
30. Itoh M, Nakajima M, Higashi E, Yoshida R, Nagata K, Yamazoe Y, Yokoi T (2006) Induction of human CYP2A6 is mediated by the pregnane X receptor with peroxisome proliferator-activated receptor-gamma coactivator 1alpha. J Pharmacol Exp Ther 319 (2):693-702. doi:jpet.106.107573 [pii] 10.1124/jpet.106.107573
31. Bock C, Reither S, Mikeska T, Paulsen M, Walter J, Lengauer T (2005) BiQ Analyzer: visualization and quality control for DNA methylation data from bisulfite sequencing. Bioinformatics 21 (21):4067-4068. doi:bti652 [pii] 10.1093/bioinformatics/bti652 (Pubitemid 41631851)
32. Yamano S, Tatsuno J, Gonzalez FJ (1990) The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry 29(5):1322-1329
33. Oscarson M, McLellan RA, Asp V, Ledesma M, Bernal Ruiz ML, Sinues B, Rautio A, Ingelman-Sundberg M (2002) Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6, 12) that causes reduced CYP2A6 activity. Hum Mutat 20(4):275-283. doi:10.1002/humu.10126
34. Pitarque M, von Richter O, Oke B, Berkkan H, Oscarson M, Ingelman-Sundberg M (2001) Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity. Biochem Biophys Res Commun 284(2):455-460. doi:10.1006/bbrc.2001.4990 S0006-291X(01)94990-94993 [pii] (Pubitemid 32917998)
35. Hukkanen J, Jacob P 3rd, Benowitz NL (2005) Metabolism and disposition kinetics of nicotine. Pharmacol Rev 57(1):79-115. doi:57/1/79 [pii] 10.1124/pr.57.1.3 (Pubitemid 40283970)
36. Higashi E, Fukami T, Itoh M, Kyo S, Inoue M, Yokoi T, Nakajima M (2007) Human CYP2A6 is induced by estrogen via estrogen receptor. Drug Metab Dispos 35(10):1935-1941. doi: dmd.107.016568 [pii] 10.1124/dmd.107.016568 (Pubitemid 47481589)
37. Parkinson A, Mudra DR, Johnson C, Dwyer A, Carroll KM (2004) The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol 199(3):193-209. doi:10.1016/j.taap.2004.01. 010 S0041008X04000638 [pii] (Pubitemid 39208721)
38. Kinirons MT, O'Mahony MS (2004) Drug metabolism and ageing. Br J Clin Pharmacol 57(5):540-544. doi:10.1111/j.1365-2125.2004.02096.x BCP2096 [pii] (Pubitemid 38582172)
39. Wortham M, Czerwinski M, He L, Parkinson A, Wan YJ (2007) Expression of constitutive androstane receptor, hepatic nuclear factor 4 alpha, and P450 oxidoreductase genes determines interindividual variability in basal expression and activity of a broad scope of xenobiotic metabolism genes in the human liver. Drug Metab Dispos 35(9):1700-1710. doi:dmd.107.016436 [pii] 10.1124/dmd.107.016436 (Pubitemid 47296067)
40. Yamazaki H, Inoue K, Hashimoto M, Shimada T (1999) Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol 73(2):65-70
41. Hart SN, Wang S, Nakamoto K, Wesselman C, Li Y, Zhong XB (2008) Genetic polymorphisms in cytochrome P450 oxidoreductase influence microsomal P450-catalyzed drug metabolism. Pharmaco-genet Genomics 18(1):11-24. doi:10.1097/FPC.0b013e3282f2f12101213011-200801000-00002 [pii]
42. Dannenberg LO, Edenberg HJ (2006) Epigenetics of gene expression in human hepatoma cells: expression profiling the response to inhibition of DNA methylation and histone deacetylation. BMC Genomics 7:181. doi:1471-2164-7-181 [pii] 10.1186/1471-2164-7-181 (Pubitemid 44468439)
43. Kerkel K, Spadola A, Yuan E, Kosek J, Jiang L, Hod E, Li K, Murty VV, Schupf N, Vilain E, Morris M, Haghighi F, Tycko B (2008) Genomic surveys by methylation-sensitive SNP analysis identify sequence-dependent allele-specific DNA methylation. Nat Genet 40(7):904-908. doi:ng.174 [pii] 10.1038/ng.174